,

Nature Reviews Drug Discovery – AMP HF

We are excited to share that Nature Reviews Drug Discovery has published a paper to announce the AMP® HF program. This paper was jointly authored by the overall PI of […]

Read more

FNIH AMP® HF Launch Announcement

The AMP® HF Program has been officially announced by the Foundation for the National Institutes of Health (FNIH).

The Foundation for the National Institutes of Health (FNIH) and the National Heart Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) are launching a new partnership to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF). Developing precision treatment strategies for HFpEF is more critical than ever, as the world’s population continues to live longer, resulting in an increase in HFpEF cases. Utilizing cutting edge technologies, including digital measurements and artificial intelligence analytic methods, the Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program is designed to find novel proteins or genes that could mitigate this disease when altered by therapeutics.

https://fnih.org/news/press-releases/fnih-announces-new-research-initiative-identify-more-precise-treatment

Please click here to view the full announcement.

AMP HF Inaugural Meeting

The inaugural meeting for the Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program will be held on September 29, 2022 at the Gaylord Hotel and Convention Center in National Harbor, Maryland.

Please visit our AMP HF Launch page for more details and announcements.